Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.80 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.80 |
| ▸ | NAMPT | P43490 | 12/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411736 | 0.93 | ACVR2A (0.72) | ACVR2ATGFBR2NAMPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL411369 | 0.89 | ACVR2A (1.00) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL414392 | 0.87 | ACVR2A (0.76) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL14490341 | 0.86 | ACVR2A (0.91) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL413609 | 0.85 | ACVR2A (0.70) | ACVR2ATGFBR2NAMPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL413843 | 0.85 | ACVR2A (0.78) | ACVR2ATGFBR2NAMPT | |
| SCHEMBL413784 | 0.85 | ACVR2A (0.75) | ACVR2ATGFBR2NAMPTROCK2 | |
| SCHEMBL411189 | 0.84 | ACVR2A (0.79) | ACVR2ATGFBR2NAMPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL412125 | 0.83 | ACVR2A (0.70) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL415573 | 0.83 | ACVR2A (0.72) | ACVR2ATGFBR2NAMPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | ACVR2A 6/4885TGFBR2 59/4885NAMPT 2618/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | ACVR2A 25/4885TGFBR2 87/4885NAMPT 2139/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | ACVR2A 26/4885TGFBR2 3/4885NAMPT 4086/4885 |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.